[vc_row][vc_column][vc_column_text] Cell and gene therapies (CGTs) offer an unprecedented opportunity to treat diseases for which existing interventions are inadequate, potentially offering cures for previously terminal illnesses. […]
[vc_row][vc_column][vc_column_text] The Drug Development IPO market enjoyed a strong third quarter, with over $3.18B raised by 26 companies across the globe, bringing the year-to-date total up […]
[vc_row][vc_column][vc_column_text]The Drug Development IPO market enjoyed a strong second quarter, with over $2.54B raised by 26 companies across the globe. 85% of companies that listed during […]
[vc_row][vc_column][vc_column_text] Swiss CDMO Lonza recently opened the world’s biggest manufacturing plant to produce custom viruses for use in cell and gene therapies. The facility, based in […]
[vc_row][vc_column][vc_column_text] The Drug Development IPO market enjoyed a strong year in 2018, with over $10.24B raised by 95 companies across 15 global exchanges. When compared to […]
[vc_row][vc_column][vc_column_text]2017 saw a total of 73 Drug Development IPOs across 15 global exchanges, compared to 58 IPOs in 2016. In total approximately $6.4B was raised, 1% […]
[vc_row][vc_column][vc_column_text] The global therapeutic IPO market has failed to maintain the upward momentum established throughout a busy Q2 2017, with just over $1B raised by 13 […]